Bluejay’s lead product candidate brelovitug (BJT-778) recently received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation for the treatment of chronic hepatitis delta (CHD).
Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation ® technology and ExPERT™ platform. In return, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback